IOVA – Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc.IOVA
$2.18Name : Iovance Biotherapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $799,697,152.00
EPSttm : -1.21
Iovance Biotherapeutics, Inc.
$2.18
1.36%$0.03Float Short %
22.45
Margin Of Safety %
Put/Call OI Ratio
0.11
EPS Next Q Diff
0.15
EPS Last/This Y
0.18
EPS This/Next Y
0.45
Price
2.17
Target Price
9.1
Analyst Recom
2.08
Performance Q
9.55
Relative Volume
0.73
Beta
0.87
Ticker: IOVA
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-09-08 | IOVA | 2.38 | 0.12 | 0.05 | 213397 |
| 2025-09-09 | IOVA | 2.37 | 0.12 | 0.02 | 215656 |
| 2025-09-10 | IOVA | 2.37 | 0.12 | 0.06 | 216888 |
| 2025-09-11 | IOVA | 2.41 | 0.12 | 0.05 | 217745 |
| 2025-09-12 | IOVA | 2.28 | 0.12 | 0.14 | 218138 |
| 2025-09-15 | IOVA | 2.29 | 0.12 | 0.08 | 214596 |
| 2025-09-16 | IOVA | 2.3 | 0.12 | 0.04 | 216491 |
| 2025-09-17 | IOVA | 2.22 | 0.12055799535004 | 0.18266129032258 | 216884 |
| 2025-09-18 | IOVA | 2.19 | 0.12 | 0.07 | 217610 |
| 2025-09-19 | IOVA | 2.05 | 0.12 | 0.07 | 220092 |
| 2025-09-22 | IOVA | 2.1 | 0.12 | 0.14 | 195023 |
| 2025-09-23 | IOVA | 2.07 | 0.12 | 0.13 | 199516 |
| 2025-09-24 | IOVA | 2.12 | 0.12 | 0.05 | 200339 |
| 2025-09-25 | IOVA | 2.02 | 0.12 | 0.13 | 203707 |
| 2025-09-26 | IOVA | 2.11 | 0.12 | 0.14 | 205819 |
| 2025-09-29 | IOVA | 2.23 | 0.12 | 0.24 | 206728 |
| 2025-09-30 | IOVA | 2.17 | 0.12 | 0.33 | 211333 |
| 2025-10-01 | IOVA | 2.21 | 0.12 | 0.05 | 212224 |
| 2025-10-02 | IOVA | 2.24 | 0.12 | 0.16 | 214544 |
| 2025-10-03 | IOVA | 2.33 | 0.12 | 0.03 | 215875 |
| 2025-10-06 | IOVA | 2.2 | 0.12 | 0.05 | 212199 |
| 2025-10-07 | IOVA | 2.16 | 0.11 | 0.19 | 216299 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-09-08 | IOVA | 2.38 | 12.5 | 80.9 | -1.10 |
| 2025-09-09 | IOVA | 2.36 | 12.5 | 63.8 | -1.10 |
| 2025-09-10 | IOVA | 2.37 | 12.5 | 60.9 | -1.10 |
| 2025-09-11 | IOVA | 2.42 | 12.5 | 51.3 | -1.10 |
| 2025-09-12 | IOVA | 2.28 | 12.5 | 89.2 | -1.10 |
| 2025-09-15 | IOVA | 2.27 | 12.5 | 60.9 | -1.10 |
| 2025-09-16 | IOVA | 2.30 | 12.5 | 53.1 | -1.10 |
| 2025-09-17 | IOVA | 2.20 | 12.5 | 80.3 | -1.10 |
| 2025-09-18 | IOVA | 2.20 | 12.5 | 61.2 | -1.10 |
| 2025-09-19 | IOVA | 2.06 | 12.5 | 93.2 | -1.10 |
| 2025-09-22 | IOVA | 2.12 | 12.5 | 42.1 | -1.10 |
| 2025-09-23 | IOVA | 2.07 | 12.5 | 71.8 | -1.10 |
| 2025-09-24 | IOVA | 2.12 | 12.5 | 48.1 | -1.10 |
| 2025-09-25 | IOVA | 2.02 | 12.5 | 84.1 | -1.10 |
| 2025-09-26 | IOVA | 2.11 | 12.5 | 36.5 | -1.10 |
| 2025-09-29 | IOVA | 2.23 | 12.5 | 29.1 | -1.10 |
| 2025-09-30 | IOVA | 2.17 | 12.5 | 72.6 | -1.10 |
| 2025-10-01 | IOVA | 2.22 | 12.5 | 47.8 | -1.10 |
| 2025-10-02 | IOVA | 2.24 | 12.5 | 51.9 | -1.10 |
| 2025-10-03 | IOVA | 2.33 | 12.5 | 41.7 | -1.10 |
| 2025-10-06 | IOVA | 2.20 | 12.5 | 70.0 | -1.10 |
| 2025-10-07 | IOVA | 2.17 | 12.5 | 69.2 | -1.10 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-09-08 | IOVA | 0.09 | -9.24 | 24.38 |
| 2025-09-09 | IOVA | 0.09 | -9.24 | 24.38 |
| 2025-09-10 | IOVA | 0.09 | -9.24 | 24.38 |
| 2025-09-11 | IOVA | 0.09 | -9.24 | 24.37 |
| 2025-09-12 | IOVA | 0.09 | -9.24 | 24.37 |
| 2025-09-15 | IOVA | 0.09 | -9.15 | 24.37 |
| 2025-09-16 | IOVA | 0.09 | -9.15 | 24.37 |
| 2025-09-17 | IOVA | 0.09 | -9.15 | 24.37 |
| 2025-09-18 | IOVA | 0.09 | -9.15 | 24.37 |
| 2025-09-19 | IOVA | 0.09 | -9.15 | 24.37 |
| 2025-09-22 | IOVA | 0.09 | -9.17 | 24.37 |
| 2025-09-23 | IOVA | 0.09 | -9.17 | 24.37 |
| 2025-09-24 | IOVA | 0.09 | -9.17 | 24.37 |
| 2025-09-25 | IOVA | 0.09 | -9.17 | 22.45 |
| 2025-09-26 | IOVA | 0.09 | -9.17 | 22.45 |
| 2025-09-29 | IOVA | 0.09 | -9.16 | 22.45 |
| 2025-09-30 | IOVA | 0.09 | -9.16 | 22.45 |
| 2025-10-01 | IOVA | 0.09 | -9.16 | 22.45 |
| 2025-10-02 | IOVA | 0.09 | -9.16 | 22.45 |
| 2025-10-03 | IOVA | 0.09 | -9.16 | 22.45 |
| 2025-10-06 | IOVA | 0.09 | -7.11 | 22.45 |
| 2025-10-07 | IOVA | 0.09 | -7.11 | 22.45 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.33
Avg. EPS Est. Current Quarter
-0.25
Avg. EPS Est. Next Quarter
-0.18
Insider Transactions
0.09
Institutional Transactions
-7.11
Beta
0.87
Average Sales Estimate Current Quarter
76
Average Sales Estimate Next Quarter
88
Fair Value
Quality Score
24
Growth Score
29
Sentiment Score
57
Actual DrawDown %
96
Max Drawdown 5-Year %
-96.8
Target Price
9.1
P/E
Forward P/E
PEG
P/S
3.27
P/B
1.07
P/Free Cash Flow
EPS
-1.23
Average EPS Est. Cur. Y
-1.1
EPS Next Y. (Est.)
-0.66
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-161.44
Relative Volume
0.73
Return on Equity vs Sector %
-81
Return on Equity vs Industry %
-67.3
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.03
EBIT Estimation
69.2
Iovance Biotherapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 838
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It develops lifileucel for treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001, an antibody cytokine engrafted protein for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
stock quote shares IOVA – Iovance Biotherapeutics, Inc. Stock Price stock today
news today IOVA – Iovance Biotherapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch IOVA – Iovance Biotherapeutics, Inc. yahoo finance google finance
stock history IOVA – Iovance Biotherapeutics, Inc. invest stock market
stock prices IOVA premarket after hours
ticker IOVA fair value insiders trading